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Abstract 11 
DNA damage repair is implemented by proteins that are coordinated by specialised molecular 12 
signals. One such signal in the Fanconi Anemia (FA) DNA-interstrand crosslink repair pathway is 13 
the site-specific monoubiquitination of FANCD2 and FANCI. The signal is mediated by a multi-14 
protein FA core complex (FA-CC) however, the mechanics for precise ubiquitination remain 15 
elusive. We show that FANCL, the RING-bearing module in FA-CC, allosterically activates its 16 
cognate E2 Ube2T to drive site-specific FANCD2 ubiquitination. Unlike typical RING E3 ligases, 17 
FANCL catalyses ubiquitination by rewiring Ube2T’s intra-residue network to influence the active 18 
site. Consequently, a basic triad unique to Ube2T engages a structured acidic patch near the target 19 
lysine on FANCD2. This three-dimensional complementarity, between the E2 active site and 20 
substrate surface, induced by FANCL is central to site-specific monoubiquitination in the FA 21 
pathway. Furthermore, the allosteric network of Ube2T can be engineered to enhance FANCL 22 
catalysed FANCD2-FANCI di-monoubiquitination without compromising site-specificity.  23 
 24 
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Introduction 26 
Ubiquitination is an essential and reversible post-translational signal that enables reprogramming of 27 
eukaryotic cellular pathways. The modification is mediated by an enzyme cascade where 28 
ubiquitin’s C-terminus is activated by an E1, transferred onto the catalytic cysteine of an E2 29 
(E2~Ub) and E3 ligases catalyse an isopeptide bond between ubiquitin and a substrate lysine1. The 30 
Really Interesting New Gene (RING) family, which share a zinc-coordinating cross-braced RING 31 
domain, represent the largest family of ubiquitin E3 ligases. Mechanistically, non-RING elements 32 
specify the substrate, while RING domains bind E2~Ub thioesters and induce substrate 33 
ubiquitination by stabilizing a productive E2~Ub conformation2. Further, ubiquitin can be targeted 34 
to build polyubiquitin chains facilitating diverse signals. Typically, RING-E2 interactions are 35 
transient, allowing the E3 to switch E2 partners and assemble polyubiquitin signals3. 36 
Approximately 35 E2s are found in mammals, several specializing in polyubiquitination. 37 
Mechanisms of linkage-specific polyubiquitination have been extensively studied, however, it is not 38 
clear how E3-E2 enzymes install ubiquitin at specific sites of non-ubiquitin substrates.  39 
Site-specific monoubiquitin signals feature in several fundamental DNA damage response 40 
pathways4. In higher eukaryotes, repair of DNA interstrand cross-links (ICLs) is mediated by the 41 
Fanconi Anemia (FA) pathway, defects in which give rise to FA, a genome instability disorder 42 
typified by bone marrow failure and high predisposition to cancers5. A key signal in the FA 43 
pathway is monoubiquitination of a specific lysine on two structurally homologous proteins, 44 
FANCD2 and FANCI (K561 and K523, respectively, in humans) which likely recruits DNA repair 45 
factors6-8. FANCD2 exists mainly in complex with FANCI9 and the mouse FANCD2-FANCI 46 
structure reveals an extensive interface that buries the monoubiquitination sites10. Genetic and cell-47 
based studies indicate that a multi-protein FA Core-Complex (FA-CC) E3 ligase activates Ube2T 48 
for site-specific monoubiquitination of FANCD2 and FANCI11,12. Mutations in Ube2T/FANCT, an 49 
E2 with a C-terminal extension, are also linked to a FA phenotype13. Within the FA-CC resides 50 
FANCL, a multi-domain RING protein that facilitates direct FANCD2/FANCI interaction and 51 
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preferentially binds Ube2T over other E2s14-17. In vitro, the isolated FANCL and Ube2T enzymes 52 
catalyse FANCD2 monoubiquitination17,18 while addition of DNA enhances ubiquitination of a 53 
FANCD2-FANCI complex, possibly by heterodimer reconfiguration that facilitates lysine 54 
access19,20. Further enhancement is observed when FANCL interacts with other FA-CC proteins 55 
(FANCB-FANCL-FAAP100 or FANCB-FANCL-FAAP100-FANCC-FANCE-FANCF sub-56 
complexes)21,22. However, mechanistic roles of FA-CC members in promoting E3 activity or 57 
directing site-specific ubiquitination are not understood. Furthermore, several lysines on human 58 
FANCD2 (32 sites) and FANCI (47 sites) are ubiquitinated in vivo23 thus the mechanism of lysine 59 
prioritisation in ICL repair is unresolved. As the repair of DNA-ICLs is crucial for cellular 60 
homeostasis, understanding how specific sites on FANCD2/FANCI are strictly monoubiquitinated 61 
would provide insights into this pathway and how specific ubiquitin signals are assembled.  62 
Here we show that FANCL activates Ube2T for ubiquitination through an allosteric mechanism 63 
distinct from classical RING E3s. We find FANCL’s interaction with Ube2T perturbs its resting 64 
state and rewires the E2-fold. These subtle reconfigurations propagate to the E2 active site where a 65 
basic triad unique to Ube2T specifies a conserved acidic patch near FANCD2’s target lysine. This 66 
three-dimensional interface between Ube2T and FANCD2 is instrumental for FANCL-induced site-67 
specific ubiquitination. Furthermore, by examining E2 residues that link FANCL binding to 68 
Ube2T’s active site, we find the allosteric network is intrinsically regulated. Using this insight, we 69 
could engineer Ube2T variants that enhance FANCL-mediated FANCD2-FANCI di-70 
monoubiquitination without compromising site-specificity. Finally, we identify similar allosteric 71 
networks in other E2s that are appropriated by RING E3s to drive specific ubiquitination.    72 
 73 
Results 74 
FANCL drives site-specificity by an atypical mechanism 75 
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Recent in vitro studies show that a partially reconstituted FA-CC, comprising the dimeric FANCB-76 
FANCL-FAAP100-FANCC-FANCE-FANCF sub-complex, induces efficient di-77 
monoubiquitination of a Xenopus FANCD2-FANCI-DNA complex22,24 (Fig. 1a). The RING-78 
bearing FANCL is embedded in this complex, however, catalytic functions of other FA-CC 79 
members are poorly defined. Importantly, FANCL autonomously directs substrate interactions and, 80 
in non-vertebrates lacking a FA-CC, mediates site-specific FANCD2 monoubiquitination16,25,26. 81 
Thus, to understand mechanisms of site-specific E3 ligase activity we chose to focus on FANCL. 82 
Full-length human FANCL is prone to aggregation and has low solubility18,22. Instead, we designed 83 
a FANCL URD-RING fragment (FANCLUR) that is stable, monomeric and comprises both 84 
substrate (UBC-RWD domain) and E2 (RING domain) binding regions16,17 (Supplementary Fig. 85 
1a). In in vitro assays, sub-stoichiometric levels of FANCLUR and Ube2T catalyse 86 
monoubiquitination of Xenopus laevis FANCD2 (xFANCD2) in the xFANCD2-xFANCI-DNA 87 
complex or in isolation (Fig. 1b). Modification of xFANCI is undetectable, however, higher 88 
FANCLUR-Ube2T concentrations stimulates weak xFANCI monoubiquitination, indicating that 89 
xFANCD2 is favoured as a substrate (Supplementary Fig. 1b). While mutations in the substrate-90 
binding patch of FANCLUR (F252A+L254A, FL/AA) and the E3-binding surface of Ube2T (F63A) 91 
individually reduce xFANCD2 monoubiquitination, mutation of the physiological site on 92 
xFANCD2 (K562R) eliminates modification, confirming site-specific activity of FANCLUR-Ube2T 93 
(Fig. 1b,c). In contrast, the well-characterised E3-E2 pair RNF4RR-Ube2D327 ubiquitinates both 94 
wildtype and mutant substrate revealing that despite other available ubiquitination sites, FANCLUR-95 
Ube2T targets a particular xFANCD2 lysine (Fig. 1d and Supplementary Fig. 1b). Previous studies 96 
show that substrate adaptors and/or additional FA-CC components enhance FANCD2 97 
monoubiquitination19-21. In agreement, we observe FANCLUR-driven xFANCD2 98 
monoubiquitination improves with excess DNA, only with xFANCI, and by swapping FANCLUR 99 
with the FANCB-FANCL-FAAP100 complex or SUMO-tagged full-length FANCL 100 
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(Supplementary Fig. 1d,e). Since FANCLUR-Ube2T alone catalyses xFANCD2 monoubiquitination, 101 
we use the minimal components to uncover the underlying mechanism of site-specific E3 activity. 102 
Mechanistic studies of RING E3s show RING domains induce a ‘closed’ conformer of the E2~Ub 103 
thioester to catalyse ubiquitination (Fig. 1d)2. In this conformation, the I44-centered hydrophobic 104 
patch of ubiquitin packs against the E2, while an arginine ‘linchpin’ RING residue braces E2~Ub, 105 
priming the thioester for lysine attack. The analogous linchpin position in FANCL is Ser363 which 106 
is unlikely to stabilize a closed E2~Ub conformer (Supplementary Fig. 1f). Therefore, we asked if 107 
FANCL requires a closed E2~Ub conformation for ubiquitination. Interestingly, the I44A ubiquitin 108 
mutant, which renders an open E2~Ub conformer, has no observable effect on site-specific activity 109 
of FANCLUR-Ube2T (Fig. 1e, Supplementary Fig. 1b). By contrast, I44A ubiquitin eliminates 110 
RNF4RR-Ube2D3 mediated ubiquitination27. As FANCLUR could stabilize other ubiquitin surfaces 111 
for E2~Ub activation, we wondered if substrate modification occurs without the globular Ub-fold. 112 
To test this, we generated a biotinylated peptide mimicking the ubiquitin tail (BiotinLRLRGG) and is 113 
activated by E128. Upon E1-E2 transthioesterification however, the peptide modifies Ube2T and 114 
impairs E2 activity. To circumvent this, we generated Ube2T1-152,K91R that lacks the auto-115 
ubiquitination sites11. Remarkably, FANCLUR-Ube2T1-152,K91R readily targets K562 xFANCD2 with 116 
BiotinLRLRGG, indicating the Ub-fold is dispensable for site-specific E3 activity (Fig. 1f). Thus, 117 
FANCLUR drives site-specific FANCD2 monoubiquitination via a mechanism distinct from generic 118 
RING E3s.  119 
 120 
Allosteric activation of Ube2T by FANCL  121 
As FANCL directs Ube2T for substrate ubiquitination, we wondered if the mechanism of site-122 
specificity could be revealed by clarifying how FANCL activates Ube2T. To investigate this, we 123 
compared structures of Ube2T29 with the FANCL RING (FANCLR) bound Ube2T17. The latter 124 
contains two E2 copies in the asymmetric unit, both superpose well with the unbound state and 125 
7 
 
show negligible global differences in the E2-fold (Fig. 2a). However, FANCLR induces local 126 
changes in Ube2T’s helix1-loop2 region (R3, D32 and D33, region I) and in loop7 (K91-K95, 127 
region II) and loop8 flanking the active site. Further, residues in beta-strands 1-2 (T23, W25, R35 128 
and Q37, region III) are reordered in the FANCLR-Ube2T structure. This region, classically known 129 
as ‘backside’ E2, can be influenced by non-RING elements to regulate ubiquitination2. Notably, 130 
Ube2T residues in each region are largely conserved (Supplementary Fig. 2a) and not in the E2-131 
FANCLR interface. We therefore wondered if these subtle changes in regions I-III feature in 132 
FANCL’s E3 mechanism. To test this, we assayed Ube2T mutants of each region and observe 133 
defects in FANCLUR mediated xFANCD2 monoubiquitination (Supplementary Fig. 3a). We 134 
extended the analysis by making hybrid mutants spanning regions I+II (D32A+D33A+L92A or 135 
DDL/AAA), region III (T23R+W25Q or TW/RQ) and all three regions 136 
(T23R+W25Q+D32A+D33A+L92A or TWDDL/RQAAA). In in vitro assays, each hybrid Ube2T 137 
mutant confers significant losses in xFANCD2 monoubiquitination (Fig. 2b). These defects could 138 
be directly linked to how FANCL activates the Ube2T~Ub thioester, or arise indirectly due to 139 
compromised E2~Ub charging and/or lysine conjugation. To discriminate this, we tested E2 140 
charging/auto-ubiquitination and find the hybrid mutants to be comparable to wildtype Ube2T 141 
(Supplementary Fig. 2b,c). In contrast, single-turnover assays reveal the mutants impair FANCLUR-142 
E2~Ub productivity and delay xFANCD2 monoubiquitination (Supplementary Fig. 3b). Thus, 143 
Ube2T mutations mitigate FANCL’s E3 activity without influencing intrinsic E2 activity.  144 
We also wondered if the hybrid Ube2T mutants influenced E3 activity of the FA-CC. In human 145 
cell-lines, mitomycin-C (MMC) induced DNA-ICLs trigger FANCD2-FANCI di-146 
monoubiquitination mediated by FA-CC/Ube2T11,13,30,31. Knockdown of Ube2T by siRNA 147 
abolishes FANCD2/FANCI modification, however, this can be rescued by transient expression of 148 
siRNA-resistant Ube2T-1D4 (Ube2T with C-terminal 1D4-tag, Fig. 2c). Interestingly, 149 
Ube2TDDL/AAA-1D4 partially rescues MMC-induced FANCD2/FANCI monoubiquitination while 150 
Ube2TTW/RQ-1D4 and Ube2TTWDDL/RQAAA-1D4 impair substrate modification. The contrast between 151 
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in vitro and cell-based FANCD2 monoubiquitination with Ube2TDDL/AAA (Fig. 2b,c) suggests E2 152 
activation is improved by the FA-CC. These data collectively reveal that Ube2T residues in regions 153 
I-III are play a role in efficient E3 activity of FANCL/FA-CC.  154 
We then analysed E3-E2 interactions to understand the basis of restricted activity. Using isothermal 155 
titration calorimetry, we observe similar affinities of FANCLUR for wildtype and Ube2TDDL/AAA 156 
(average Kd ~ 119 nM) while Ube2T
TW/RQ displays a modest binding defect (Kd = 200 nM) (Fig. 157 
2d). The affinity of FANCLR-Ube2T is unaltered by the mutations (average Kd ~ 253 nM) 158 
(Supplementary Fig. 3c), but interestingly, is 2-fold weaker than FANCLUR-Ube2T. Thus, a non-159 
RING element in FANCLUR, likely the URD, supports Ube2T interactions via the E2’s backside. 160 
The smaller FANCLR fragment, which lacks substrate-binding URD16, is expectedly weaker than 161 
FANCLUR in site-specific xFANCD2 monoubiquitination (Supplementary Fig. 3d). However, 162 
comparing relative activities of FANCLR and FANCLUR with each hybrid Ube2T mutant reveals 163 
that Ube2TDDL/AAA reduces K562 xFANCD2 monoubiquitination regardless of the E3 employed. In 164 
contrast, Ube2TTW/RQ impairs only FANCLUR-driven reactions indicating that the longer E3 165 
fragment binds distinct E2 regions to stimulate activity. We also uncover thermodynamic variations 166 
that reflect a bimodal influence of FANCLUR for Ube2T activation (Fig. 2e and Supplementary 167 
Table 1). Despite comparable binding energies (ΔG), the large binding entropy (-TΔS) observed 168 
with FANCLUR-Ube2T interaction (-15.75 kcal/mol) is diminished by TW/RQ and DDL/AAA 169 
mutations in Ube2T and by URD deletion in FANCL (-12.55, -7.64 and -12.70 kcal/mol, 170 
respectively). The reduced entropy is likely associated with smaller conformational changes in 171 
Ube2T upon E3-binding and accounts for weakened substrate ubiquitination. Taken together, the 172 
analyses suggest FANCL-binding influences the E2-fold to allosterically activate Ube2T for 173 
FANCD2 monoubiquitination.  174 
 175 
E2 active site and FANCD2 devise site-specificity 176 
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FANCL’s E3 mechanism likely involves subtle changes within Ube2T, therefore, we generated 177 
residue interaction networks (RINs) to uncover the mechanics of allosteric activation. Such 178 
networks plot E2 residues as nodes while edges represent physicochemical interactions in the 179 
tertiary structure. Comparison of unbound and FANCLR-bound Ube2T RINs reveals 180 
edges/interactions unique to each network, together representing a ‘dynamic’ RIN (Supplementary 181 
Fig. 4a and Supplementary Dataset 1). Here we chose E2 nodes/residues that support FANCLR-182 
binding as initial search nodes to trace connected neighbours, which then serve as successive search 183 
nodes. By iteration, we trace possible paths between the FANCLR-binding cluster and E2 active 184 
site, focusing on conserved nodes and regions I-III, while filtering out diverging paths. The final 185 
allosteric network model represents how FANCLR-binding rewires the intra-molecular connections 186 
of Ube2T and likely activates substrate ubiquitination (Fig. 3a). Notably, the network termini in the 187 
catalytic beta-element (R84), loop7 (K91 and K95), loop8 and its C-terminal hinge (D122 and 188 
L124, respectively) lie within 10Å of Ube2T’s catalytic cysteine (C86, Fig. 3a inset) and could 189 
regulate FANCL-induced FANCD2 ubiquitination. Conversely, given their proximity to C86 they 190 
could also regulate E2 activity. In several E2s, a hydrophobic residue (L124 in Ube2T) is crucial for 191 
E1~Ub-E2~Ub transthioesterification32 while a loop8 residue (D122 in Ube2T) positions and/or 192 
deprotonates the target lysine27 (Supplementary Fig. 4b). The remaining Ube2T network termini 193 
(R84, K91 and K95) vary among ubiquitin E2s and mutational analysis (R84S, K91A, K95A and 194 
R84S+K91A+K95A or RKK/SAA) reveals no impact on E3 interaction or E2~Ub charging with a 195 
minor E2 auto-ubiquitination defect11 (Supplementary Fig. 2b,2c,4c and Supplementary Table 1). In 196 
contrast, each single mutant impedes xFANCD2 monoubiquitination, while Ube2TRKK/SAA 197 
eliminates both in vitro and cell-based substrate monoubiquitination (Fig. 3b,c). Thus, the Ube2T 198 
basic triad (R84, K91 and K95) are required exclusively for FANCL/FA-CC driven substrate 199 
monoubiquitination but are dispensable for fundamental E2 activity.  200 
We wondered if this catalytic paradox underlies FANCL’s mechanism for site-specific FANCD2 201 
monoubiquitination. Intriguingly, through analysis of the mouse FANCD2 structure10 and sequence 202 
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homology, we notice a conserved acidic patch proximal to the target lysine (Fig. 3d). In theory, the 203 
Ube2T basic triad could mediate electrostatic interactions with FANCD2’s acidic patch and 204 
stabilize the E2-substrate intermediate for ubiquitination. To test this, we generated a series of 205 
charge-reversal mutations in xFANCD2’s acidic patch (D555R+D554R, D555R+D521R and 206 
D555R+D554R+D521R) and Ube2T’s basic triad (R84E+K91D, K91D+K95D and 207 
R84E+K91D+K95D). In in vitro assays, none of the acidic patch xFANCD2 mutants are 208 
ubiquitinated by FANCLUR-Ube2T (Fig. 3e). Remarkably, FANCLUR catalyses 209 
xFANCD2D555R+D554R and xFANCD2D555R+D521R monoubiquitination using Ube2TR84E+K91D and 210 
Ube2TK91D+K95D, respectively. Moreover, monoubiquitination of xFANCD2 dyad mutants is 211 
mutually exclusive, implying that productive E2-substrate interactions occur in a specific 212 
configuration. Finally, FANCLUR-Ube2TR84E+K91D+K95D efficiently monoubiquitinates 213 
xFANCD2D555R+D554R+D521R, however, does not modify xFANCD2 or the patch mutant lacking the 214 
target lysine (xFANCD2D555R+D554R+D521R+K562A, Fig. 3e and Supplementary Fig. 4d). These results 215 
reveal that the basic triad in Ube2T and a target acidic patch on FANCD2 are critical for site-216 
specificity. Furthermore, unlike typical RING E3s3, FANCLUR does not enhance reactivity of the 217 
E2~Ub thioester towards free nucleophiles (Supplementary Fig. 4e). Thus, the catalytic outcome of 218 
FANCL-Ube2T is fine-tuned for a specific, three-dimensionally structured substrate surface. In 219 
summary, FANCL facilitates productive interactions between the basic triad in Ube2T’s active site 220 
and a structured target acidic patch on FANCD2, thus enforcing site-specific ubiquitination. 221 
 222 
E2 allosteric conduit regulates site-specific E3 activity  223 
Site-specific FANCD2 monoubiquitination involves modulation of Ube2T’s active site, therefore, 224 
the allosteric network model likely includes residue connections that orchestrate FANCL’s 225 
activation of Ube2T (Fig. 3a). A long-range network (D33-R35-E54-R69-A82) propagates through 226 
Ube2T regions I and III, culminating at the catalytic beta-element where R84 resides. In particular, 227 
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the R69 side-chain is secured by E54 in unbound Ube2T, however, this link is altered upon FANCL 228 
binding (Fig. 4a). Consequently, R69 is free to stabilize the catalytic beta-element, which could 229 
facilitate interactions between Ube2T R84 and FANCD2’s target acidic patch. In other words, an 230 
effector role for R69 could be gated by E54 in Ube2T’s resting state and allosterically relieved by 231 
FANCL to trigger substrate ubiquitination. We tested this hypothesis using Ube2T E54A/Q/R 232 
mutants, which would disrupt ionic E54-R69 interactions, and observe enhanced FANCLUR-driven 233 
K562 xFANCD2 monoubiquitination, while a conservative Ube2TE54D mutant retains Ube2T-like 234 
activity (Fig. 4b, Supplementary Fig. 5a). Meanwhile, Ube2TR69A, which would prevent hydrogen 235 
bonding between R69 and catalytic beta-element, reduces FANCLUR-driven K562 xFANCD2 236 
monoubiquitination, while a conservative Ube2TR69K mutant rescues this defect. Notably, E54 and 237 
R69 mutants do not alter intrinsic Ube2T activity (Supplementary Fig. 2b,c). To further investigate 238 
the gating-effector conduit, we determined the structure of Ube2TE54R to 2.0Å resolution 239 
(Supplementary Table 2). The E2-fold of Ube2TE54R is overall similar to unbound Ube2T, however, 240 
certain local changes are observed (Supplementary Fig. 5b-d). Loop2 (region I) is reordered while 241 
the E54R mutation forms a salt-bridge with D33. Consequently, the R69 side-chain is repositioned 242 
within hydrogen bonding distance of the catalytic beta-element (Fig. 4c). These subtle changes in 243 
the gating-effector conduit of Ube2TE54R are reminiscent of FANCLR-bound Ube2T and could 244 
represent an ‘activated’ E2 state. Remarkably, in single-turnover assays, the Ube2TE54R~Ub 245 
thioester catalyses E3-independent xFANCD2 monoubiquitination to a similar extent as the 246 
FANCLUR-Ube2T~Ub pair (Fig. 4d, Supplementary Fig. 5e). Therefore, E54 operates as a 247 
molecular gate that restricts Ube2T for FANCD2 ubiquitination, however, is rendered permissive 248 
by FANCL-binding or targeted mutagenesis.   249 
Curiously, the basic triad configuration in Ube2TE54R resembles unbound more than FANCLR-250 
bound Ube2T (Supplementary Fig. 6a). To investigate active site dynamics, we performed all-atom 251 
molecular dynamics simulations with Ube2TE54R and Ube2T structures. We observe no significant 252 
differences in the E2 backbone, however, differences in side-chain configurations of the basic triad 253 
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were discernible (Supplementary Fig. 6b). Notably, the R84/K91 side-chain(s) are more likely to 254 
adopt distinct conformation(s), with respect to C86, mainly in Ube2TE54R trajectories. In absence of 255 
an E2-substrate intermediate structure, we cannot unambiguously define a ‘catalytic conformation’ 256 
for Ube2T’s basic triad. Nevertheless, we speculate that the steadied conformation(s) for R84/K91 257 
in Ube2TE54R may be responsible for substrate ubiquitination and could stem from R69 (effector) 258 
influencing the catalytic beta-element. Concurrently, the R69A mutation in Ube2T, that impedes 259 
FANCLUR-activation (Fig. 4b), also reverts xFANCD2 modification induced by Ube2TE54R (Fig. 260 
4d, Supplementary Fig. 5e). Thus, FANCL optimises Ube2T’s active site for site-specific FANCD2 261 
monoubiquitination via dynamics of the gating-effector conduit.    262 
We wondered if such regulatory conduits exists in other E2s involved in specific ubiquitin signals. 263 
For example, repair pathways that support bypass of stalled DNA replication are initiated upon site-264 
specific (K164) monoubiquitination of Proliferating Cell Nuclear Antigen (PCNA) by the E3-E2 265 
pair Rad18-Ube2B(Rad6B)33. The Rad18-Ube2B interaction is bimodal, with the canonical RING-266 
E2 interface supported by Rad18’s Rad6 binding domain (R6BD) interacting with backside E234. 267 
Comparing networks/structures of unbound and R6BD-bound E2s, we notice a potential gating-268 
effector (E58-R71) conduit in Ube2B (Fig. 4e, Supplementary Dataset 2), which is distal from the 269 
bimodal Rad18-Ube2B interface. In in vitro assays, Ube2BE58R improves while Ube2BR71A weakens 270 
Rad18 mediated PCNA monoubiquitination, however, neither mutant alters intrinsic E2 activity, 271 
thus revealing their regulatory roles in substrate modification (Fig. 4f, Supplementary Fig. 7a,b). It 272 
is currently unknown if Ube2B active site residues interact with PCNA. We speculate the gating-273 
effector conduit modulates substrate ubiquitination by stabilizing the catalytic beta-element in 274 
Ube2B. Taken together, these results suggest that regulatory conduits may operate across the E2 275 
family and could be leveraged by E3s for specific ubiquitin signals. 276 
 277 
Ube2T engineering enhances substrate ubiquitination 278 
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Based on Ube2T’s allosteric network, we successfully engineered a permissive gate (E54R) that 279 
enhances FANCD2 monoubiquitination. We wondered if other Ube2T regions could be similarly 280 
exploited. The K91/K95 pair in region II are critical for target acidic patch interactions, suggesting 281 
the dynamics of loop7 (K91LPPK95) might influence substrate ubiquitination. While FANCLR-282 
binding draws loop7 away from the active site and rewires a short-range network leading into 283 
region II (Fig. 2a,3a), the presence of two conserved prolines (P93 and P94, Supplementary Fig. 2a) 284 
rigidifies this loop. We reasoned a flexible loop7 could emulate the dynamics observed with 285 
FANCL-binding and/or increase the likelihood of K91/K95 interactions with FANCD2’s target 286 
acidic patch. Therefore, we engineered a flexible loop7 (P93G+P94G) and observe an improvement 287 
in K562 xFANCD2 monoubiquitination by FANCLUR-Ube2TP93G+P94G, however, not with isolated 288 
Ube2TP93G+P94G (Fig. 5a, Supplementary Fig. 8a). A plausible explanation for this contrast is the 289 
restrictive gate (E54) in isolated Ube2TP93G+P94G. Consequently, we generated another variant, 290 
Ube2Tv3, comprising both a permissive gate (E54R) and flexible loop7 (P93G+P94G). The 291 
isolated Ube2Tv3 can stimulate efficient K562 xFANCD2 monoubiquitination (Fig. 5b) 292 
furthermore, is superior to Ube2TE54R and Ube2TP93G+P94G, revealing a synergistic effect of the 293 
mutations. Remarkably, Ube2Tv3 in combination with FANCLUR catalyses xFANCD2 294 
monoubiquitination to near completion without compromising site-specificity. Furthermore, sub-295 
stoichiometric levels of FANCLUR-Ube2Tv3 can also catalyse K524 xFANCI monoubiquitination 296 
(Supplementary Fig. 8b), albeit more weakly than xFANCD2. The FANCI surface10 has a spatially 297 
constricted acidic patch near the target lysine (Supplementary Fig. 8c), which correlates with lower 298 
ubiquitination. Importantly, it reveals how the three-dimensional configuration of the target acidic 299 
patch regulates the efficiency of substrate monoubiquitination.  300 
The engineered permissive gate (Ube2TE54R) influences R84/K91 conformations while loop7 301 
flexibility (Ube2TP93G+P94G) likely permits more conformational freedom for K91/K95. Therefore, 302 
enhanced activity of Ube2Tv3 could arise from optimised interactions between the basic triad and 303 
the target acidic patch. Alternatively, increased dynamics/flexibility of the engineered E2-fold may 304 
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improve E2~Ub thioester reactivity. To clarify this, we analysed E2-substrate interactions using 305 
microscale thermophoresis. Interestingly, a weak Ube2T-xFANCD2 interaction (Kd = 320±22 M) 306 
is detectable, dependent on both the target acidic patch and the basic triad (Fig. 5c). With Ube2Tv3, 307 
we observe a minor improvement in xFANCD2 interaction (Kd = 238±20 M) that may contribute 308 
to enhanced substrate ubiquitination. We also examined E2~Ub thioester stability and its 309 
nucleophile reactivity. Ube2Tv3~Ub is marginally more stable than Ube2T~Ub while, 310 
unexpectedly, aminolysis is slowed (Fig. 5d, Supplementary Fig. 8d). These data suggest Ube2Tv3 311 
is more adept at targeting the structured substrate lysine with an organised acidic patch than a free 312 
lysine. In summary, the underlying enhancement in Ube2Tv3-driven substrate ubiquitination is 313 
multifactorial and includes subtle reordering of the basic triad, minor improvements in substrate 314 
interaction, increased E2~Ub thioester stability and an optimal configuration of the target acidic 315 
patch.  316 
 317 
FANCL-Ube2Tv3 catalyse FANCD2-FANCI ubiquitination   318 
As the engineered Ube2Tv3 efficiently catalyses monoubiquitination of isolated FANCD2/FANCI, 319 
we assessed ubiquitination of the xFANCD2-xFANCI-DNA complex and find FANCLUR-Ube2Tv3 320 
improves both the rate and level of xFANCD2 monoubiquitination (7- and 4-fold, respectively) 321 
relative to FANCLUR-Ube2T (Fig. 6a, Supplementary Fig. 9a). Further, we observe a remarkable 322 
improvement in xFANCI monoubiquitination with ~40% of the substrate modified. Overall, di-323 
monoubiquitination of the DNA-bound heterodimer by the minimal FANCLUR-Ube2Tv3 module is 324 
comparable to the reconstituted FA-CC/Ube2T setup22. Moreover, FANCLUR-Ube2Tv3 does not 325 
compromise site-specificity and partially overcomes the requirement of DNA for efficient 326 
xFANCD2-xFANCI di-monoubiquitination (Supplementary Fig. 9b). The contrasting 327 
monoubiquitination profiles for xFANCI, isolated versus the heterodimer, indicates that xFANCD2 328 
influences the efficiency of xFANCI modification (Fig. 6a, Supplementary Fig. 8b). In vivo, 329 
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phosphorylation of S/TQ motifs in FANCI is reported to regulate substrate ubiquitination35,36 while 330 
FANCD2-binding reconfigures FANCI’s S/TQ motifs10 placing them proximal to the target lysine 331 
(Supplementary Fig. 8c). Thus, phosphorylation and the presence of FANCD2 could together 332 
optimise FANCI’s target acidic patch and promote its monoubiquitination.  333 
Curiously, levels of xFANCI monoubiquitination in a xFANCD2K562R-xFANCI-DNA complex 334 
regress to those observed with isolated xFANCI. (Supplementary Fig. 8b,9b). In the former, a 335 
K562R mutation prevents xFANCD2 modification, thus implying efficient xFANCI modification 336 
depends both on xFANCD2 and its monoubiquitinated state. To test this, we devised an orthogonal 337 
E2-substrate assay using Ube2TR84E+K91D+K95D (T−), which specifies a basic patch on 338 
xFANCD2D555R+D554R+D521R (D2+), and Ube2Tv3 (T+), which requires the acidic patch on xFANCI 339 
(I–). In ubiquitination assays of a DNA-bound D2+-I– complex, FANCLUR-T+ exclusively 340 
monoubiquitinates I–, while conversely, FANCLUR-T– selectively monoubiquitinates D2+, 341 
validating the orthogonal setup (Fig. 6b, Supplementary Fig. 9c). Surprisingly, I– 342 
monoubiquitination is improved when both T– and T+ are present in the reaction, despite the former 343 
E2 being nonreactive on I–. Therefore, the D2+-Ub product, catalysed by FANCLUR-T–, stimulates 344 
I– monoubiquitination by FANCLUR-T+, confirming our hypothesis. Overall, these results indicate 345 
that precise ubiquitination is mediated by FANCL-Ube2T acting on the target acidic patch, 346 
however, di-monoubiquitination of FANCD2-FANCI is inherently sequential and is regulated by an 347 
interplay between the DNA-bound heterodimer. 348 
 349 
Discussion 350 
Monoubiquitination of FANCD2 and FANCI is a critical signal in the FA-ICL repair pathway37. 351 
Previous studies on FANCL, the catalytic FA-CC subunit, revealed substrate binding features of the 352 
UBC-RWD16 and an extended RING-E2 interface that underlies selective E2 recruitment17. In this 353 
study, we uncover the molecular mechanism by which FANCL-Ube2T catalyses site-specific 354 
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FANCD2 monoubiquitination. Unlike most RING E3s, FANCL lacks the classical ‘linchpin’ that 355 
primes a productive E2~Ub thioester conformation2. Rather than stabilizing the ubiquitin-fold, 356 
FANCL instead stimulates the E2-fold of Ube2T through the RING-E2 interface and backside E2 357 
interactions, likely via the UBC-RWD. This bimodal and high-affinity FANCL-Ube2T interaction 358 
rewires the E2’s intra-residue network thereby allosterically influencing its active site. Notably, we 359 
find a basic triad unique to Ube2T’s active site and a conserved acidic patch near FANCD2’s target 360 
lysine license FANCL’s site-specific E3 activity. Reports on site-specific modification by 361 
ubiquitin/ubiquitin-like proteins reveal how E3-substrate interactions guide the E2-E3 complex to a 362 
lysine targeting zone38-41. Meanwhile, studies on linkage-specific polyubiquitination show how E2 363 
interactions with ubiquitin residues near the target lysine regulate site-specificity42-46. 364 
Mechanistically, FANCL-Ube2T mirrors these strategies in that substrate docking by FANCL’s 365 
UBC-RWD restricts the lysine-targeting area of the RING-bound E2, while electrostatic 366 
complementarity between Ube2T’s basic triad and FANCD2’s target acidic patch fine-tunes the 367 
lysine-targeting zone. However, unique to this E3-E2 pair is the allosteric activation of Ube2T by 368 
FANCL that optimises the E2’s active site for productive interactions with FANCD2’s target acidic 369 
patch, thereby driving site-specific ubiquitination (Fig. 6c). In fact, FANCL’s allosteric activation 370 
of Ube2T is uniquely adapted for a three-dimensionally structured surface thus precluding any 371 
spurious ubiquitination. As we do not observe processive modification, either on the installed 372 
ubiquitin or a different FANCD2 site, neither surface is optimally recognized by FANCL-Ube2T, 373 
restricting ubiquitination to a single event. 374 
Our structure-guided analysis also reveals the allosteric trigger, i.e. the gating-effector couple in 375 
Ube2T, which underlies FANCL’s activation mechanism. In unbound Ube2T, a gating residue 376 
(E54) restricts an effector residue (R69) from influencing the active site. However, FANCL binding 377 
frees this restraint, which likely restructures the active site to promote site-specific substrate 378 
ubiquitination. Interestingly, mutations of the gating residue yield deregulated E2s that improve 379 
both FANCL-dependent and -independent FANCD2 monoubiquitination, without compromising 380 
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site-specificity. We find analogous pairs in several other E2s that could potentially function as 381 
gating-effector residues (Supplementary Fig. 10) and validate this feature for Ube2B/Rad6B, an E2 382 
responsible for site-specific PCNA monoubiquitination. Recent efforts in designing E2 inhibitors 383 
have uncovered promising fragments that bind near this regulatory pair and allosterically alter E2 384 
activities47,48. These observations collectively suggest that allosteric networks operate across the E2 385 
family and could prove instrumental for understanding specificity in ubiquitin signalling. 386 
By elucidating FANCL’s atypical E3 activity and the underlying mechanics of site-specificity, we 387 
successfully engineered a catalytically-enhanced E2 variant, Ube2Tv3, which substantially 388 
improves FANCD2-FANCI di-monoubiquitination. Thus, substrate-binding and site-specificity are 389 
essentially inherent to the FANCL-Ube2T module, consistent with studies in non-vertebrates 390 
lacking a FA-CC25,26. Importantly, we show that Ube2T activation and optimization of the target 391 
acidic patch on FANCD2/FANCI are two critical factors that influence the efficiency of site-392 
specific monoubiquitination. We propose that substrate adaptors and/or FA-CC members serve 393 
these functions. Indeed, several studies have demonstrated how FANCI/DNA improve FANCD2 394 
monoubiquitination18-20. Given their intimate relationship with FANCD2, FANCI/DNA are ideal 395 
candidates for reconfiguring FANCD2’s target acidic patch. The FANCC-FANCE-FANCF 396 
complex has also been suggested to modulate the FANCI-FANCD2-DNA complex to promote di-397 
monoubiquitination22,24. In addition, the FANCB-FANCL-FAAP100 complex is reported to 398 
enhance FANCD2 ubiquitination21. We propose that Ube2T activation could be augmented when 399 
FANCL is embedded in this complex. FANCI phosphorylation reportedly regulates substrate 400 
ubiquitination36 and may optimise FANCI’s target acidic patch. Moreover, we find efficient FANCI 401 
monoubiquitination relies on ubiquitinated FANCD2. Conversely, FANCI phosphorylation 402 
reportedly impedes activity of the cognate deubiquitinating enzyme USP135, thus favouring the 403 
ubiquitinated state. Evidently, the monoubiquitination status of FANCI-FANCD2 is regulated at 404 
multiple levels. Using the engineered E2-E3 pair we have designed a method49 that can readily 405 
generate natively monoubiquitinated FANCD2 and FANCI. This will enable characterisation of the 406 
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ubiquitinated substrates, both in isolation and as a complex. Moreover, this approach has been 407 
instrumental in revealing how the site-specific ubiquitin signal on FANCD2 is removed by USP150. 408 
Similarly, the monoubiquitinated products could provide insights into their interactions with DNA, 409 
the temporal nature of di-monoubiquitination and facilitate discovery of downstream readers of the 410 
signal.  411 
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 540 
Figure Legends (for main text only) 541 
Fig 1. | FANCL driven site-specific FANCD2 monoubiquitination does not require the core 542 
Ubiquitin fold.  543 
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a, Current in vitro model for FANCD2-FANCI monoubiquitination. A partially reconstituted 544 
Fanconi Anemia - Core Complex (FA-CC) comprising the dimeric FANCB-FANCL-FAAP100-545 
FANCC-FANCE-FANCF sub-complex activates Ube2T for efficient and site-specific di-546 
monoubiquitination of a Xenopus FANCD2-FANCI heterodimer bound to DNA. The FANCL 547 
URD-RING (FANCLUR) fragment is the core E3 ligase module in the FA-CC. b, In in vitro 548 
reactions, the FANCLUR-Ube2T pair catalyses site-specific monoubiquitination of Xenopus 549 
FANCD2 (xFANCD2/xD2) present in the xFANCD2-xFANCI-DNA substrate complex as well as 550 
in isolation. Reactions were carried out in the absence or presence of dsDNA (81 bp) as indicated. 551 
‘Wt’ denotes wildtype substrate, ‘KR’ denotes K562R mutation for xFANCD2 and K524R for 552 
xFANCI. A breakdown in wildtype xFANCD2 is denoted by ‘*’. c, In vitro xFANCD2 553 
ubiquitination using a FANCLUR mutant (F252A+L254A, FL/AA) that weakens substrate binding 554 
or a Ube2T mutant (F63A) that weakens E3 interaction both result in a decrease in xFANCD2 555 
monoubiquitination. Average percentage of monoubiquitinated FANCD2 from three independent 556 
experiments is reported. d, Site-specific monoubiquitination of xFANCD2 is catalysed by the 557 
FANCLUR-Ube2T pair but not the RNF4RR-Ube2D3 pair of E3-E2 enzymes. e, Site-specific 558 
xFANCD2 monoubiquitination by FANCLUR-Ube2T does not require the I44 Ubiquitin based 559 
closed conformation of the E2~Ub thioester. f, The FANCLUR-Ube2T1-152, K91R pair drives site-560 
specific modification of xFANCD2 using a biotinylated Ubiquitin tail peptide (BiotinLRLRGG). Raw 561 
images in Supplementary Fig. 11. 562 
Fig 2. | FANCL induced changes in Ube2T contribute to FANCD2 monoubiquitination.  563 
a, Superpose of FANCL RING (FANCLR, blue) bound Ube2T (orange, PDB ID 4ccg) on unbound 564 
Ube2T (grey, PDB ID 1yh2) shows minimal global changes in the E2-fold (residues 1-152, Cα 565 
RMSD ~ 0.8Å) upon FANCLR binding. Dashed boxes and corresponding close-ups of Ube2T 566 
regions I, II and III reveal local changes in the E2-fold. b, FANCLUR mediated in vitro xFANCD2 567 
ubiquitination is compromised by Ube2T mutations in the indicated regions. A breakdown in 568 
xFANCD2 is denoted by ‘*’. DDL/AAA, TW/RQ and TWDDL/RQAAA denote Ube2T mutations 569 
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D32A+D33A+L92A, T23R+W25Q and T23R+R25Q+D32A+D33A+L92A, respectively. Graphs 570 
represent percentage xFANCD2 monoubiquitination (n=3) with a line at mean value. Significant 571 
differences were assessed by one-way ANOVA with Dunnett’s multiple-comparison test. Adjusted 572 
P values are shown. c, U2OS cells transfected with the indicated siRNA and expression vector 573 
(empty/Ube2T-1D4) were treated with DNA crosslinking agent mitomycin-C (MMC, 0.3 µM) as 574 
indicated. Experiment schematic is shown above and cell-lysates were analysed by immunoblotting. 575 
Mutations in Ube2T reduce monoubiquitination of FANCD2 and FANCI. Average percentage from 576 
two biological replicates is reported. Ube2T mutations as in panel b. Raw images in Supplementary 577 
Fig. 11. d, Raw and experimental fits of isothermal calorimetric titration of Ube2T to FANCLUR 578 
and (e) the associated thermodynamic components (∆G, ∆H and -T∆S) as bar graphs (values in 579 
Supplementary Table 1). Despite comparable binding energies (∆G), a reduction in binding entropy 580 
(-T∆S) suggest smaller conformational changes in the mutant E2-E3 complex. Ube2T mutants as in 581 
panel b.  582 
Fig 3. | Basic triad in Ube2T active site and target acidic patch on FANCD2 licence site-583 
specific ubiquitination. 584 
a, Allosteric network model (38 nodes, 74 edges) shows rewiring of Ube2T intra-residue network 585 
upon FANCLR interaction. Dashed and orange lines depict connections in free and FANCLR-bound 586 
E2, respectively. Black boxes indicate nodes involved in FANCLR binding and in regions I-III. The 587 
catalytic cysteine (C86, yellow) and the proximal network termini (Sγ-Cβ distances ≤ 10Å in 588 
unbound Ube2T (inset), PDB ID 1yh2) have a thick outline, with the basic triad (R84, K91 and 589 
K95) coloured in blue. The catalytic beta-element includes nodes 82-86. Grey nodes have relative 590 
solvent accessibility of <10% in free Ube2T. b, Mutations of Ube2T’s basic triad impair FANCLUR 591 
mediated xFANCD2 ubiquitination. RKK/SAA denotes Ube2T mutant R84S+K91A+K95A. 592 
Graphs represent percentage xFANCD2 monoubiquitination (n=3). Significant differences were 593 
assessed by one-way ANOVA with Dunnett’s multiple-comparison test. Adjusted P values are 594 
shown.  c, U2OS cells transfected with the indicated siRNA and expression vector (empty/Ube2T-595 
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1D4) were treated with mitomycin-C (MMC) as indicated. Experiment schematic is shown above 596 
and cell-lysates were analysed by immunoblotting. Average percentage of FANCD2 and FANCI 597 
monoubiquitination from two biological replicates is reported. d, FANCD2 sequence alignment 598 
showing conservation of acidic residues (red/orange) proximal to target lysine (blue). Structure of 599 
mouse FANCD2 (PDB ID 3s4w) depicts acidic residue configuration in relation to target lysine 600 
(Cβ-Cβ distances ≤ 13Å) Surface electrostatic potential is colour scaled from −2 kT/e (red) to +2 601 
kT/e (blue). e, Functional significance of Ube2T’s basic triad and xFANCD2’s target acidic patch is 602 
assessed by in vitro ubiquitination assays using the indicated charge-reversal mutations. The 603 
FANCLUR-Ube2TR84E+K91D and FANCLUR-Ube2TK91D+K95D enzyme pair’s monoubiquitinate 604 
xFANCD2D555R+D554R and xFANCD2D555R+D521R, respectively, in a mutually exclusive manner. 605 
Consequently, FANCLUR-Ube2TR84E+K91D+K95D exclusively monoubiquitinates 606 
xFANCD2D555R+D554R+D521R. Raw images in Supplementary Fig. 11. 607 
Fig 4. | Specialised residue pair within the E2-fold regulates RING E3 driven substrate 608 
ubiquitination. 609 
a, Comparison of a residue network with structures of unbound (grey, PDB ID 1yh2) and FANCLR-610 
bound (orange, PDB ID 1yh2) Ube2T depicting the proposed allosteric conduit. The E54 functions 611 
as a gating residue based on its influence on R69, which in turn acts as an effector residue for 612 
stabilising the catalytic beta-element. b, FANCLUR mediated in vitro xFANCD2 ubiquitination 613 
using Ube2T mutants of the gating and effector residues. Graphs represent percentage xFANCD2 614 
monoubiquitination (n=3) with a line at mean value. Significant differences were assessed by one-615 
way ANOVA with Dunnett’s multiple-comparison test. Adjusted P values are shown.  c, Structure 616 
of Ube2T gating mutant E54R (magenta) reveals a bonding network in the allosteric conduit similar 617 
to the FANCLR-bound Ube2T structure. d, Monoubiquitination of xFANCD2 (1 µM) under single-618 
turnover conditions shows reactivity of the indicated E2~Ub thioester (1 µM) in the absence or 619 
presence of FANCLUR (1 µM). Percentage of xFANCD2 monoubiquitination (mean ± range, n=3) 620 
is plotted over time. To prevent E2 auto-ubiquitination, Ube2T1-152, K91R is used and indicated 621 
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mutations incorporated in this background. e, Comparison of a residue network with structures of 622 
unbound Ube2B (grey, PDB ID 2yb6) and Rad6 Binding Domain (R6BD) bound Ube2B (green, 623 
PDB ID 2ybf) depicting the proposed gating and effector roles for Ube2B residues E58 and R71, 624 
respectively. f, Immunoblots of in vitro ubiquitination assays shows Ube2B with a permissive gate 625 
(E54R) is more responsive to Rad18 in PCNA monoubiquitination, while the Ube2B effector 626 
mutant (R71A) slows the reaction. Percentage of PCNA-Ub (n=3) were quantified, linear rates 627 
normalized to Rad18-Ube2B wildtype reaction and plotted with a line at mean value. Raw images 628 
in Supplementary Fig. 11. 629 
Fig 5. | Ube2Tv3 enhances E3-dependent and E3-independent FANCD2 monoubiquitination.  630 
a, b, Monoubiquitination of xFANCD2 (n=3) is improved by a Ube2T variant with a flexible loop7 631 
(Ube2TP93G+P94G) only in the presence of FANCLUR. In contrast, xFANCD2 monoubiquitination is 632 
enhanced by Ube2Tv3, which includes a permissive gate (E54R) and a flexible loop7 633 
(P93G+P94G), both in the presence and absence of FANCLUR. Reactions were also performed with 634 
xFANCD2 K562R mutant to assess site-specificity. c, MST dose-response-curves for interactions 635 
between Ube2T (Ligand) against xFANCD2 (Target). Curves were fitted to a one-site binding 636 
model for Kd determination and plotted against baseline corrected normalized fluorescence (Δ Fnorm 637 
[‰]). Mutation of the target acidic patch on xFANCD2 (D555R+D554R+D521R or 638 
xFANCD2DDD/RRR) or a basic residue in Ube2T’s active site (R84S) weakens or abolishes E2-639 
substrate interactions. A minor improvement in xFANCD2 interaction is observed with Ube2Tv3. 640 
To allow for high ligand concentrations, Ube2T1-152 is used and indicated mutations incorporated in 641 
this background. All measurements were done in triplicates, error bars indicate standard deviation. 642 
d, Single-turnover assays to assess hydrolysis and aminolysis (20 mM lysine) of the E2~Ub 643 
thioester (3 µM). To prevent E2 auto-ubiquitination, Ube2T1-152, K91R is used and mutations 644 
incorporated in this background. Percentage of E2~Ub (n=3) were plotted over time and fitted with 645 
one-phase decay model (see Supplementary Fig. 7d for best-fit values and the goodness of fit). k 646 
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denotes the rate constant (%E2~Ub.min-1). The Ube2Tv3~Ub thioester is relatively more stable 647 
than Ube2T~Ub in both reactions. Raw images in Supplementary Fig. 11. 648 
Fig 6. | Monoubiquitination of FANCD2 regulates efficiency of FANCI monoubiquitination.  649 
a, A time-course ubiquitination assay of the xFANCD2-xFANCI-DNA complex using FANCLUR-650 
Ube2T (left) or FANCLUR-Ube2Tv3 enzyme pairs (right). Percentage of substrate 651 
monoubiquitination (n=3) was determined from anti HA (xFANCD2) and anti V5 (xFANCI) 652 
immunoblots. Values were plotted over time and fitted with one-phase accumulation model (see 653 
Supplementary Fig. 8a for best-fit values and the goodness of fit). t1/2 denotes reaction half-time in 654 
minutes. b, FANCLUR catalysed ubiquitination assays of the DNA bound substrate heterodimer 655 
using orthogonal E2-substrate pairs. T− denotes Ube2T with an acidic active site (black square, 656 
Ube2TR84E+K91D+K95D) that can modify xFANCD2 with a basic target patch (open white square, D2+, 657 
xFANCD2D521R+D554R+D555R). T+ denotes the enhanced Ube2Tv3 (Ube2TE54R+P93G+P94G) with a basic 658 
active site (black triangle) that can modify substrates with a target acidic patch (open white 659 
triangles, xFANCD2 (D2−) or xFANCI (I−)). In the I−-D2+-DNA complex, the FANCLUR-T+ and 660 
FANCLUR-T− enzyme pair’s monoubiquitinate I− and D2+, respectively, in a mutually exclusive 661 
manner. However, levels of I− monoubiquitination increase both T− and T+ are present indicating 662 
that monoubiquitinated D2+ improves efficiency of I− modification. Raw images in Supplementary 663 
Fig. 11. c, Model for FANCL catalysed site-specific FANCD2 ubiquitination. FANCL mediates 664 
substrate docking via its central UBC-RWD domain (URD) and selectively recruits Ube2T 665 
primarily via the RING domain. FANCLUR binding of Ube2T allosterically influences a basic triad 666 
in the E2 active site. The optimised active site promotes productive encounters with target acidic 667 
patch on FANCD2 and thereby catalyses site-specific ubiquitination. 668 
 669 
Online Methods 670 
Plasmids, oligonucleotides and peptides. 671 
27 
 
Human Ube2T and Ube2D3 (I.M.A.G.E. clone, Geneservice) were inserted using restriction 672 
cloning into a modified pET15 vector (Novagen) harbouring a 3C-cleavable 6xHis-tag sequence at 673 
the N-terminus. Human Ube2B (I.M.A.G.E. clone, Geneservice) was inserted via Gateway Cloning 674 
(Invitrogen) into a modified pDEST17 vector (Invitrogen), harbouring a TEV-cleavable 6xHis-tag 675 
sequence at the N-terminus. A synthetic human FANCL sequence (GeneArt) was used as template 676 
to insert FANCL (residue 1-375), FANCLUR (residues 109-375) and FANCLR (residues 289-375) 677 
coding regions into a pET SUMO vector (Invitrogen) using restriction-free cloning. All FANCL 678 
constructs harbour a 6xHis-smt3 tag at the N-terminus. A synthetic human Rad18 sequence 679 
(GeneArt) was inserted by restriction cloning into a modified pET28a (Novagen) harbouring a 680 
6xHis-smt3 tag at the N-terminus. The Xenopus laevis FANCD2, FANCI (gifts from Prof. J.C. 681 
Walter, Harvard) and human Uba1 genes were inserted into modified pFBDM vectors harbouring 682 
an N-terminal 6xHis-TEV-HAtag, 6xHis-TEV-V5tag and 6xHis-TEV, respectively, via restriction 683 
cloning. Codon optimised synthetic FANCB, FANCL and FAAP100 genes (GeneArt) were inserted 684 
into a single pFBDM vector by sequential restriction cloning. A 6xHis-FLAGtag was inserted at the 685 
N-terminus of FANCB. Human PCNA (gift from Dr Svend Petersen-Mahrt, IFOM-FIRC Institute 686 
of Molecular Oncology, Milan), was inserted using restriction cloning into a pRSF Duet1 vector 687 
(Novagen), that harbours a 6xHis-tag at the N-terminus. Ubiquitin was inserted using restriction 688 
cloning into a modified pRSF Duet1 vector that harbours a 6xHis-TEV at the N-terminus. Silencer 689 
Select Negative Control No. 1 and Custom Silencer Select Ube2T siRNA duplexes (siT1 - 690 
5’AGAGAGAGCUGCACAUGUUTT 3’, siT2 - 5’UCUAAGUUGCCUACCUUGATT 3’, siT3 - 691 
5’UCUAAGUUGCCUACCUUGATT 3’) described previously11 were purchased from Life 692 
Technologies. A Ube2T gene with silent mutations to disrupt siRNA complementarity and a C-693 
terminal 1D4-tag was synthesised (GeneArt) and inserted into a pcDNA5/FRT vector (Invitrogen). 694 
Various DNA cofactors for ubiquitination of the FANCD2-FANCI heterodimer have been 695 
previously described19. For this study, the following oligonucleotides were synthesised and obtained 696 
as PAGE purified duplex DNA (IDT technologies).  697 
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O10 - TTGATCAGAGGTCATTTGAATTCATGGCTTCGAGCTTCATGTAGAGTCGACGGTGCTGGGATCCAACATGTTTTCAATCTG  698 
O11 - CAGATTGAAAACATGTTGGATCCCAGCACCGTCGACTCTACATGAAGCTCGAAGCCATGAATTCAAATGACCTCTGATCAA 699 
All PCR reactions were carried out using Phusion High-Fidelity DNA polymerase (Thermo 700 
Scientific) except for mutagenesis which were generated using primer-based inverse PCRs using 701 
KOD Hot Start DNA polymerase (Novagen). Custom oligonucleotides for PCR and mutagenesis 702 
were obtained from Sigma Aldrich or IDT technologies. The coding regions of all constructs and 703 
mutants were verified by automated DNA sequencing using MRC PPU DNA Sequencing and 704 
Services or Eurofins Genomics DNA sequencing services. The biotinylated ubiquitin tail peptide 705 
(BiotinLRLRGG) was custom synthesised (GenScript) to >95% purity and trifluoroacetic acid 706 
exchanged with hydrochloric salt. 707 
 708 
Expression and purification of recombinant proteins 709 
The expression and purification of Ube2T and FANCL fragments (FANCLUR/FANCLR) has been 710 
previously described16,17,49.  The 6xHis-smt3-Rad18 and 6xHis-MBP-rat RNF4 RING-RING 711 
(RNF4RR) proteins was purified as described elsewhere27,34. Bacmid preparation, baculovirus 712 
generation, expression and purification of FANCD2, FANCI and Uba1 proteins is as described 713 
elsewhere49. Bacmid preparation, baculovirus generation and expression of 6xHis-FLAGtag-714 
FANCB-FANCL-FAAP100 were similar to FANCD2/FANCI. Purification of 6xHis-FLAGtag-715 
FANCB-FANCL-FAAP100 involved Ni-NTA affinity, anion-exchange and gel-filtration 716 
chromatography. All purification steps were performed at 4°C and completed within 24-36 hours of 717 
cell lysis. Buffer solutions for protein purification are made using ultrapure water (resistivity of 18.2 718 
MΩ cm at 25 °C) and kept cold. The constructs for ubiquitin, Ube2D3, Ube2B and PCNA were 719 
transformed into chemically competent BL21 (DE3) E. coli cells (Invitrogen) and cultured in Miller 720 
LB broth (Fisher) at 37°C until OD600 ~ 0.4 following which temperature was reduced to 16°C. At 721 
OD600 ~ 0.8, protein expression was induced by adding a final concentration of 500 μM Isopropyl-722 
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Beta-d-Thiogalactopyranoside (IPTG, Formedium) and allowed to proceed for a further 16-18h. 723 
Cell lysis and affinity purification of ubiquitin, Ube2D3, Ube2B and PCNA is similar to that 724 
described for Ube2T. The affinity tags were cleaved using GST-3C (for Ube2T and Ube2D3), 725 
6xHis-Ulp1 (for FANCLUR/FANCLR) and 6xHis-TEV (for ubiquitin, RNF4 and Ube2B) proteases, 726 
respectively, that were made in-house. The 6xHis-tag on PCNA and the 6xHis-smt3 on RAD18 and 727 
FANCL (full-length) were retained. The ubiquitin, Ube2D3, Ube2B and 6xHis-PCNA proteins 728 
were subject to gel-filtration chromatography as described for FANCL 49. For all FPLC runs ӒKTA 729 
Pure chromatography systems (GE Life Sciences) were used. All purified proteins were 730 
concentrated using Amicon Ultra Centrifugal filters (Merck) with the desired Molecular Weight Cut 731 
Off. All proteins were flash-frozen in liquid nitrogen as single-use aliquots and stored at -80˚C.  732 
 733 
In vitro substrate ubiquitination assays 734 
Frozen protein aliquots were thawed on ice and reactions were performed on the same day. All 735 
reactions were carried out in 50 mM HEPES pH 7.6, 100 mM NaCl, 1 mM Tris 2-carboxyethyl-736 
phosphine (TCEP), 2 mM MgCl2 and 4% (v/v) glycerol buffer system at 30°C. For monitoring 737 
substrate ubiquitination, 20-100 μL reactions containing 50 nM 6xHis-Uba1, 5 μM Ubiquitin (or 738 
6xHis Ub where indicated), 250 nM of Ube2T and FANCLUR (unless indicated otherwise) and 1 739 
μM of xFANCD2 or xFANCI substrates in isolation. In case of the substrate complex, 1 μM of 740 
xFANCD2 and xFANCI were mixed with 2 μM of DNA and used for the reaction. Reaction mixes 741 
were prepared on ice, equilibrated to room-temperature and initiated by addition of Adenosine 742 
triphosphate (ATP) at a final concentration of 2.5 mM. At the desired time-points, reaction samples 743 
were terminated with 2xLDS sample buffer (Pierce) containing 7.5% (v/v) β-mercaptoethanol, and 744 
heated at 98°C for 3min. For visualizing reaction products, 3 μL of the terminated samples were 745 
resolved using Novex 4-12% Tris-Glycine Mini Gels, WedgeWell format (Invitrogen), stained 746 
overnight using InstantBlue Coomassie stain (Expedeon) and de-stained by extensive washes with 747 
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distilled water. For immunoblotting, 1.5 μL of the terminated samples were resolved in the same gel 748 
system. Refer Immunoblots and Antibodies for transfer procedure and detection reagents. 749 
Coomassie stained gels and immunoblotted membranes were scanned by direct fluorescence 750 
monitoring using the Odyssey CLX Imaging System (Li-COR) and quantification were carried out 751 
using Image Studio software (v4.0.21).  752 
For assays with the RNF4RR-Ube2D3 pair, 250 nM of the E3-E2 pair was used instead of 753 
FANCLUR-Ube2T. For assays with the biotinylated ubiquitin tail peptide (BiotinLRLRGG), 50 μL 754 
reactions contained 200 nM 6xHis-Uba1, 50 μM BiotinLRLRGG, 1 μM of Ube2T1-152,K91R and 755 
FANCLUR and 2 μM of xFANCD2 or xFANCD2 K562R. For PCNA ubiquitination assays, 30 μL 756 
reactions contained 50 nM 6xHis-Uba1, 10 μM Ubiquitin, 3 μM of Ube2B, 6xHis-smt3-Rad18 and 757 
6xHis-PCNA. At the indicated time-points, reaction samples were mixed with 2xLDS sample buffer 758 
(Pierce) containing 7.5% (v/v) β-mercaptoethanol and terminated by heating at 98°C for 3min. 759 
Samples were resolved using NuPAGE 4-12% Bis-Tris Gels (Invitrogen) and analysed by 760 
immunoblotting   761 
For single-turnover xFANCD2 ubiquitination assays, E2 charging reactions (30 μL) contained 150 762 
nM 6xHis-Uba1, 12.5 μM Ubiquitin and 10 μM E2 and started with ATP (2.5 mM final). To 763 
prevent auto-ubiquitination, the Ube2T1-152,K91R variant was used and mutations of interest were 764 
made in this background. After 10 min at 30°C, 0.25 U of Apyrase (NEB) was added, the reaction 765 
diluted to 60 μL with assay buffer and left at room temperature for 5 min to hydrolyse the ATP. The 766 
E2~Ub charging efficiency was determined to be ~80%. The E2~Ub discharge mix (45 μL) 767 
contained ~1 μM of E2~Ub, 1 μM FANCLUR (unless indicated otherwise) and 1 μM of xFANCD2. 768 
At the indicated time-points, reaction samples were mixed with 3 μL of 3xLDS sample buffer 769 
(Pierce) containing 3 mM TCEP. Reaction products were resolved using NuPAGE 4-12% Bis-Tris 770 
Gels (Invitrogen) and visualised by InstantBlue Coomassie staining as above.  771 
 772 
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E2 charging, auto-ubiquitination and nucleophile reactivity assays  773 
Frozen protein aliquots were thawed on ice and reactions were performed on the same day. All 774 
reactions were carried out in 50 mM HEPES pH 7.6, 100 mM NaCl, 1 mM Tris 2-carboxyethyl-775 
phosphine (TCEP), 2 mM MgCl2 and 4% (v/v) glycerol buffer system at 30°C. E2 charging 776 
reactions (10 or 30 μL) contained 150 nM 6xHis-Uba1, 12.5 μM Ubiquitin and 10 μM E2. 777 
Reactions were commenced by addition ATP (2.5 mM final), maintained at 30°C and samples were 778 
taken at the indicated time-points. To terminate the reaction, samples were mixed with 3xLDS 779 
sample buffer (Pierce) containing 3 mM TCEP. E2 auto-ubiquitination reactions (10 μL) containing 780 
100 nM 6xHis-Uba1, 12.5 μM Ubiquitin and 10 μM E2 and Ubiquitin were maintained at 30°C. At 781 
the indicated time-point, samples were mixed with 3xLDS sample buffer (Pierce) containing 7.5% 782 
(v/v) β-mercaptoethanol and heated at 98°C for 3min. To observe both E2 charging and auto-783 
ubiquitination, 0.75-1 μg of each E2 was resolved using NuPAGE 4-12% Bis-Tris Gels (Invitrogen) 784 
and visualised by InstantBlue Coomassie staining as above. For nucleophile reactivity assays, the 785 
Ube2T1-152,K91R variant was used to prevent E2 auto-ubiquitination and desired mutations were 786 
made in this background. E2 charging reactions (50 μL) contained 150 nM 6xHis-Uba1, 7.5 μM E2 787 
and 10 μM Ub and started with ATP (2.5 mM final). After 10 min at 30°C, 0.25 U of Apyrase 788 
(NEB) was added and left at room temperature for 5 min to hydrolyse the ATP. The E2~Ub 789 
discharge mix (50 μL) contained ~3 μM of E2~Ub in assay buffer containing 2 mM 790 
Hydroxylamine-HCl (Pierce) or 20 mM L-lysine (Sigma) or no nucleophile. The reactivity of each 791 
nucleophile was also assessed in the presence of 5 μM FANCLUR. The E2~Ub discharge reactions 792 
were carried out at 30°C and at the depicted time-points, reaction samples were terminated with 793 
3xLDS sample buffer (Pierce) containing 3 mM TCEP. Reaction products were resolved using 794 
NuPAGE 12% (Supplementary Fig. 4d) or 4-12% (Fig. 5c) Bis-Tris Gels (Invitrogen) and 795 
visualised by InstantBlue Coomassie staining as above.  796 
 797 
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Cell based substrate ubiquitination assays  798 
Human U2OS (osteosarcoma) cells (ATCC# HTB-96, Lot# 70008732) were purchased from the 799 
American Type Culture Collections and maintained in McCoy’s 5a medium (Sigma) with L-800 
Glutamine, sodium bicarbonate and 10% (v/v) Foetal Bovine Serum (full-medium). All experiments 801 
were carried out with low-passage cells (<15) of good viability (>95%). siRNA transfections were 802 
performed in a 12-well dish using reverse transfection. In each well, 15 pmol of siRNAs and 4.5 μL 803 
Lipofectamine RNAiMAX (Invitrogen) were mixed in 100 μL of Opti-MEM I reduced serum 804 
medium and incubated for 20 min. To this mix, U2OS cells (0.2-0.25x106) in full-medium were 805 
added and final volume made up to 1 mL/well. After 24 hr, cells were washed with Dulbecco’s 806 
Phosphate Buffered Saline without CaCl2 and MgCl2 (Invitrogen) and full-medium was added. 807 
After 12 hr of the medium change, each well was transfected with 1 μg of vector using ViaFect 808 
(Promega) following manufacturer’s protocol. After 12 hr of vector transfection, the medium was 809 
replaced with 1 mL of full-medium containing 0.3 μM Mitomycin-C (MMC, Sigma) dissolved in 810 
dimethyl sulfoxide (DMSO, Sigma) or equal amount of DMSO. After 12hr of MMC/DMSO 811 
treatment cells were harvested and whole-cell lysates were prepared by lysing cells in 50 mM Tris-812 
HCL pH 6.8, 2.5% SDS, 6% (v/v) β-mercaptoethanol and heating at 98°C for 10 min. Lysates (~25 813 
μg) were resolved using Novex 4-12% Tris-Glycine Mini Gels, WedgeWell format (Invitrogen) and 814 
subject to immunoblotting. Refer Immunoblots and Antibodies for transfer procedure and detection 815 
reagents.  816 
 817 
Immunoblots and Antibodies 818 
All gels were transferred onto nitrocellulose membranes using the iBlot Gel Transfer Device 819 
(Invitrogen) set at P3 (20 V) and 8 min. Membranes were blocked using 1x Phosphate buffered 820 
saline (PBS, Fisher Bioreagents) containing with 5% (w/v) milk powder (Marvel) and 0.05% (v/v) 821 
Tween20 (Sigma). The membranes were incubated overnight at 4°C in blocking buffer containing 822 
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the desired primary antibodies. Blots were washed 3x15 min with 1xPBS buffer with 0.05% v/v 823 
Tween20 and where required probed with IRDye 800CW or 680RD labelled secondary antibodies 824 
(Li-COR) at 1/10,000 dilution for 2 h at room-temperature. Blots were washed 3x15 min with 825 
1xPBS buffer with 0.05% v/v Tween20 and scanned by direct fluorescence monitoring using 826 
Odyssey CLX Infrared Imaging System (Li-COR). The primary antibodies used in this study are as 827 
listed in Supplementary Table 3. 828 
 829 
Isothermal titration calorimetry 830 
ITC experiments were performed using MicroCal PEAQ-ITC (Malvern). All experiments were 831 
performed at 20°C, in duplicate, using freshly purified proteins. Proteins were buffer exchanged 832 
using 7K MWCO Zeba Spin Desalting Columns (Pierce) into 100 mM Tris-HCl, 100 mM NaCl, 833 
0.4 mM TCEP buffer at pH 8.0 that was filtered and degassed. FANCLUR (ranging 22 to 34 μM) 834 
and FANCLR (~32 μM) was held in the cell, while Ube2T (ranging 400 to 600 μM) was present in 835 
the syringe. A total of 16 injections were carried out with the first injection of 0.3 μL/0.6 s followed 836 
by 15 injections of 1.5 μL/3 s. All injections were spaced by 120 s with mix speed set at 500 837 
rotations per minute. Each experiment was controlled by an identical E2 into buffer run to account 838 
for the heat of dilution. All data were fitted with a single-site binding model using MicroCal PEAQ-839 
ITC analysis software (v1.0). 840 
 841 
Microscale Thermophoresis 842 
MST measurements were performed using Monolith NT.115 (Nanotemper). All experiments were 843 
performed at 20°C, in triplicate, using freshly purified ligand protein (Ube2T1-152). The Ube2T1-152 844 
fragment was used as it tolerates the high ligand concentrations required for interaction analysis. 845 
The target, 6xHis-HA-xFANCD2, was labelled in binding buffer (50 mM HEPES pH 7.5, 100 mM 846 
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NaCl, 4 mM DTT, 1% (w/v) Ovalbumin) using His-Tag Labeling Kit RED-tris-NTA 2nd 847 
generation (Monolith) following the manufacturers guidelines. The ligand proteins were 848 
concentrated and buffer exchanged into binding buffer using 7K MWCO Zeba Spin Desalting 849 
Columns (Pierce). Ligands, at 3 mM, were diluted across a 16-point (2:1) dilution series in low 850 
binding tubes. Each dilution was mixed with the labelled target at a final concentration of 35 nM. 851 
The reaction mixture were loaded into premium capillaries (Monolith) and analysed at 100% LED 852 
power and 40% MST power. The Pre-MST, MST-acquisition and post-MST periods were 3 s, 15 s 853 
and 1 s, respectively. The resulting dose-response curves were fitted to a one-site binding model for 854 
Kd determination inbuilt in the MO.Affinity Analysis software (v2.3, Nanotemper). Fluorescence 855 
from the cold/pre-MST (-1.0 to -0.5 s) and hot/MST-acquisition (0.1 to 0.6 s) periods were used for 856 
Kd determination. 857 
  858 
Residue Network Analysis 859 
PDB files were first processed through the PDB-REDO webserver (https://pdb-redo.eu/) and 860 
Residue Interaction Networks (RINs) generated using the RIN generator webserver 861 
(http://protein.bio.unipd.it/ring/)51. Networks were generated for consecutive residues, excluding 862 
water molecules and hetero atoms, using relaxed (Ube2T) and strict (Ube2B) distance thresholds. 863 
Network policy was set to closest and all atoms of the residue pair are considered however, only the 864 
single most energetic interaction type was outputted. The output files were uploaded in Cytoscape 865 
(v3.6.1), and the RINs were compared using the RINalyzer (v2.0.0)52 using node identifier as 866 
matching attribute. In case of Ube2T, two copies of the RING bound state were individually 867 
compared to the unbound state using edge difference weighting. The resulting RIN comparison 868 
matrices were merged using the merge network tool in Cytoscape. Molecular figures prepared in 869 
PyMOL (v2.0.5). 870 
 871 
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Crystallization and Structure determination 872 
The Ube2T E54R was concentrated to 24 mg/mL and used for sitting drop vapour diffusion 873 
crystallisation with various commercial screens. Crystals appeared in multiple conditions at 4˚C. 874 
Diffraction quality crystals from the condition 0.1 Μ Tris-HCl pH 8.5, 20% v/v glycerol ethoxylate, 875 
3% v/v poly(ethylene imine) were cryoprotected with 20% (v/v) glycerol and flash-frozen in liquid 876 
nitrogen. Native X-ray diffraction datasets were collected at 0.996 Å, 100 K on the ID30A-877 
1/MASSIF-1 beamline at ESRF synchrotron (Grenoble, France) on a CMOS Hybrid Pixel detector 878 
(Dectris Pilatus3 2M) at phi scans of 0.15° at. Indexing and integration were performed using 879 
iMosflm(v7.2.2)53 and the reduced data scaled using AIMLESS(v0.7.3)54. The structure was solved 880 
using molecular replacement with Phaser(v2.8.2)55 with PDB ID 1yh2 as the search model. Manual 881 
model building and automated refinement were performed iteratively using COOT(v.0.8.9.2)56 and 882 
REFMAC5(v5.8.0238)57, respectively. No electron density observed for Ube2T C-terminus, 883 
residues 154-197, and are absent in the final model. The final model contained 98.1% of residues in 884 
favoured regions and 100% in allowed regions of the Ramachandran plot (no outliers). 885 
 886 
Molecular Dynamics Simulations 887 
All MD simulations (80 ns x 3) were performed using GROMACS (v5.1.1)58 using experimentally 888 
determined X-ray structures as starting point (PDB IDs: 4ccg, 1yh2, and the Ube2T E54R structure 889 
(6r75)). The all-atom force field AMBER99SB59 was used for the simulation. The starting 890 
structures were solvated using the TIP3P water model with water box extending 10Å from the 891 
outermost protein atom. The systems were neutralised with addition of Na+ and Cl- ions and 892 
equilibrated before and after insertion of ions. Production simulations were performed at constant 893 
temperature and pressure with periodic boundary conditions imposed in all directions. All bonds 894 
with hydrogen atoms were constrained by the LINCS algorithm and Coulomb interactions were 895 
computed with the PME method. For electrostatic and van der Waals interactions, 10Å cut off 896 
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values were used. The simulations were run for 80 ns and the first 80 ps were removed prior to 897 
analysis. The analysis was performed using standard procedures (g_rmsf, g_dist) within the 898 
GROMACS package. 899 
 900 
Statistical Analysis 901 
All gels and membranes were scanned by direct fluorescence monitoring using the Odyssey CLX 902 
Imaging System (Li-COR) and quantification were carried out using the associated Image Studio 903 
software (v4.0.21). Custom shapes were used to quantify intensities of the total and ubiquitinated 904 
substrate. After average background subtraction, the trimmed signal intensities were exported into 905 
Microsoft Excel (2016) to calculate percentage of ubiquitination. Where reported, statistical 906 
significance of the difference from the FANCLUR-Ube2T reaction was assessed by one-way 907 
analysis of variance with Dunnett’s multiple-comparison test. For quantifying 908 
hydrolysis/aminolysis of the E2~Ub thioester, percentage of E2~Ub were fitted with one-phase 909 
decay mode using the equation Y= (Y0 - plateau)* e
-kt + plateau. Y0 and plateau is percentage 910 
E2~Ub at 0 min and infinite time, respectively, k is the rate constant (%E2~Ub.min-1), t is time 911 
(min) and half-time (t1/2) = ln(2)/k (min). For quantifying ubiquitination of the FANCD2-FANCI 912 
heterodimer, percentage of ubiquitination were fitted with one-phase accumulation model using the 913 
equation Y= plateau(1 - e-kt). Plateau is percentage substrate ubiquitination at infinite time, k is the 914 
rate constant (%Ub.min-1), t is time (min) and half-time (t1/2) = ln(2)/k (min). All statistical analysis 915 
and graph generation were carried out in GraphPad Prism (v8.1.2). 916 
 917 
Data Availability 918 
The atomic coordinates and structure factors have been deposited in the Protein Data Bank under 919 
accession code 6r75. Other data and materials are available from the corresponding authors upon 920 
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reasonable request or from the MRC Protein Phosphorylation and Ubiquitylation Unit reagents Web 921 
page (http://mrcppureagents.dundee.ac.uk). 922 
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